XE-991
SIGMA/X2254 - ≥98% (HPLC)
Synonym: 10,10-
CAS Number: 122955-42-4
Empirical Formula (Hill Notation): C26H20N2O
Molecular Weight: 376.45
MDL Number: MFCD05662331
Linear Formula: C26H20N2O
Product Type: Chemical
assay | ≥98% (HPLC) |
color | white to beige |
InChI | 1S/C26H20N2O/c29-25-21-5- |
InChI key | KHJFBUUFMUBONL-UHFFFAOYSA |
originator | Merck & Co., Inc., Kenilworth, NJ, U.S. |
Quality Level | 100 ![]() |
SMILES string | O=C1c2ccccc2C(Cc3ccncc3)( |
solubility | DMSO: >20 mg/mL |
storage temp. | 2-8°C |
Application: | XE-991 has been used as a KCNQ (Kv7.2/7.3) inhibitor to examine whether M-current inhibition affects oxytocin receptor (TGOT) mediated depolarization. It has also been used as an KCNQ inhibitor to study the ionic mechanism responsible for the overshoot/undershoot in membrane potential in mouse cholinergic interneurons (ChIs) in the presence of tetrodotoxin (TTX). |
Biochem/physiol Actions: | XE-991 is a KCNQ channel blocker; which is more potent than linopiridine (Cat. No. L-134). |
Features and Benefits: | This compound is featured on the Potassium Channels ![]() ![]() |
Features and Benefits: | This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S. ![]() ![]() |
Packaging: | 10, 50 mg in glass bottle |
Symbol | ![]() |
Signal word | Warning |
Hazard statements | H315 - H319 - H335 |
Precautionary statements | P302 + P352 - P305 + P351 + P338 |
Hazard Codes | Xi |
Risk Statements | 36/37/38 |
Safety Statements | 26-36 |
RIDADR | NONH for all modes of transport |
WGK Germany | WGK 3 |
Flash Point(F) | Not applicable |
Flash Point(C) | Not applicable |
Purity | ≥98% (HPLC) |
Storage Temp. | 2-8°C |
UNSPSC | 12352200 |